BioSpace News Archive

AstraZeneca and FibroGen Inc. (FibroGen) today presented pooled efficacy and cardiovascular (CV) safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease (CKD).

AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF).

Veeva Systems (NYSE:VEEV) today announced it has acquired Physicians World, a leading provider of speakers bureau services.

Urania Therapeutics, a biopharmaceutical company specializing in the identification and development of ‘readthrough’ compounds, today announces it has successfully raised €3.53M ($3.89M) in seed funding to unlock the therapeutic potential of ribosome-based treatments.

INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2019 and is providing a business update.

FibroGen, Inc. (NASDAQ:FGEN), today announced results from the pooled analyses of data from six global pivotal Phase 3 trials investigating roxadustat, a first-in-class, orally-administered inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity.

As published in The New England Journal of Medicine, Feinstein Institutes for Medical Research investigators found that patients undergoing hemodialysis who had moderate-to-severe pruritus experience a significant reduction in itch intensity and an increase in quality of life after they received the drug difelikefalin (CR845)

Trio Health, a leading provider of real-world evidence, today announced results from four studies presented at the Liver Meeting of the American Association for the Study of Liver Diseases.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that new data from its ongoing Phase 2 clinical trial in glioblastoma multiforme will be presented at the Society for Immunotherapy of Cancer Annual Meeting by Lead Principal Investigator Dr. Daniela Bota.

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, today announced the successful completion of a $100 million Series B financing.